neurotrophin receptor associated death domain, pseudogeneGenealiases: []
Q-omics provides the consensus-scored NRADDP profile across patient tissues and cancer cell-line models. NRADDP expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NRADDP is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, NRADDP RNA expression shows 13,724 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where NRADDP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRADDP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRADDP survival associations across molecular data types. NRADDP RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRADDP RNA expression–survival associations across cancer types. High NRADDP expression shows unfavorable associations in KIRC and ACC, but favorable associations in HNSC, UCS, UVM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NRADDP RNA expression.
This table summarizes NRADDP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NRADDP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRADDP shows lower tumor expression in HNSC, LUAD, LUSC and KICH and higher tumor expression in COAD and CHOL. The COAD box plot shows higher NRADDP RNA expression in tumor versus normal tissue (log2 FC = +0.653, t-test p < 0.001).
This table shows molecular features associated with NRADDP in patient tissues and cancer cell lines. In patient samples, NRADDP shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
